**Amendments to the Claims**:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1 - 14. (Canceled)

15. (New) Method of treatment of a disease involving a neuronal connectivity defect comprising administering to an individual in need thereof a therapeutic effective amount of one epothilone or derivative thereof.

16. (New) Method according to claim 15, wherein the disease includes a psychotic or psychiatric disorder.

17. (New) Method according to claim 15, wherein the epothilone is a compound of formula (I):




(I)

wherein:

$R^1$ represents H, alkyl, alkenyl or alkynyl in $C_1$-$C_6$, aryl in $C_6$-$C_{10}$, aralkyl in $C_7$-$C_{15}$,

$R^2$, $R^3$ represents each H or form together C=C double bond,

$R^4$ represents H, $C_1$-$C_6$-alkyl in particular $CH_3$, fluoro substituted $C_1$-$C_6$ alkyl in particular $CF_3$ or $CFH_2$,

$R^5$ and $R^6$ form a C=C double bond or a three membered ring including O, S, $NR^7$, $CR^8R^9$ with $R^7$ being $C(O)R^{10}$, $SO_2R^{10}$ and $R^8$, $R^9$, $R^{10}$ being independently H, halogen, $C_1$-$C_6$ alkyl, $C_6$-$C_{10}$ aryl, $C_7$-$C_{15}$ alkaryl,

$R^{11}$ being H, $C_1$-$C_6$ alkyl, $C_6$-$C_{10}$ aryl, $C_7$-$C_{15}$ alkaryl, and in particular H,

W represents $C(R^{12})$=CH, $C(R^{12})$=$C(CH_3)$, $C(R^{12})$=CF or a bicyclic aromatic/heteroaromatic radical preferably a 2-methylbenzothiazol-5-yl radical, or a 2-methylbenzoxazol-5-yl radical or a quinolin-7-yl radical, with $R^{12}$ representing a heteroaromatic radical, preferably a 2-pyridinyl, a 2-substituted thiazol-4-yl or a 2-substituted oxazol-4-yl radical with substitution in 2-position by $C_1$-$C_6$ alkyl, pseudohalogen like CN or $N_3$, S-$C_1$-$C_4$-alkyl, O-$C_1$-$C_6$-alkyl, or $C_1$-$C_6$-alkyl substituted by OH, amino, halogen, pseudohalogen such as –NCO, -NCS, $-N_3$ , O-($C_1$-$C_6$)-acyl, O-($C_1$-$C_6$)-alkyl or O-benzoyl,

X-Y represents O-C(=O), O-$CH_2$ , $CH_2$-O, $CH_2$-C(=O),

Z represents C=O, S, S=O, $SO_2$,

$R^{13}$ and $R^{14}$ represents independently from each other H, $C_1$-$C_6$-alkyl, $(CO)R^{15}$ or $C_{1-4}$-trialkylsilyl, with $R^{15}$ being H, $C_1$-$C_6$-alkyl, fluoro substituted $C_1$-$C_6$-alkyl,

and pharmaceutically acceptable salts thereof.

18. (New) Method according to claim 15, wherein the epothilone is a derivative of following formula (II):




(II)

wherein:

R'$^4$ represents an $C_1$-$C_6$ alkyl or substituted $C_1$-$C_6$ alkyl with substituents as F, Cl, Br or I, pseudohalogen, such as –NCO, -NCS , $-N_3$ , $NH_2$, OH, O-($C_1$-$C_6$)-acyl, O-($C_1$-$C_6$)-alkyl or O-benzoyl,

$R'^1$ and $R'^2$ are independently from each other H, $C_1$-$C_6$-alkyl, $(CO)R'^5$ with $R'^5$ being H, $C_1$-$C_6$-alkyl, $C_1$-$C_6$-fluoroalkyl or $C_{1-4}$-trialkylsilyl,

$R'^3$ represents H, $C_1$-$C_6$-alkyl, halogen substituted $C_1$-$C_6$-alkyl, and

Y and Z form either a C=C double bond or are the O atom of an epoxide and pharmaceutically acceptable salts thereof.

19. (New) Method according to claim 18, wherein the epothilone is at least a derivative of formula (II) wherein $R'^1$, $R'^2$, $R'^3$ represents independently from each other, H, $C_1$-$C_6$-alkyl in particular $CH_3$, $C_1$-$C_6$ fluoroalkyl in particular $CF_3$ and Y and Z form either a C=C double bond or are together the O atom of an epoxide.

20. (New) Method according to claim 15, wherein epothilone includes at least the natural epothilone A or B of following formula:




Epothilone A




Epothilone B

or a pharmaceutically acceptable salt thereof.

21. (New) Method according to claim 15, wherein epothilone includes at least one synthetic epothilone C, D, E or F of following formula:




Epothilone C




Epothilone D




Epothilone E




Epothilone F

in particular epothilone D and pharmaceutically acceptable salts thereof.

22. (New) Method according to claim 15, wherein epothilone includes at least one synthetic epothilone of following formula:



















23 (New) Method according to any claim 15, wherein the epothilone is used at a therapeutically effective amount from about 0.01/Kg/dose to about 100 mg/Kg/dose.

24. (New) Method according to claim 15, wherein the epothilone or derivative thereof is administered in pharmaceutical composition comprising at least a pharmaceutically acceptable carrier.